Literature DB >> 31918059

Effects of ALOX5, IL6R and SFTPD gene polymorphisms on the risk of lung cancer: A case-control study in China.

Xiaoping Wei1, Chen Wang2, Haiming Feng2, Bing Li2, Peng Jiang2, Jianbao Yang2, Duojie Zhu2, Shaobo Zhang2, Tao Jin2, Yuqi Meng2.   

Abstract

BACKGROUND: ALOX5, IL6R and SFTPD are all immune related genes that may be involved in the development of lung cancer. We sought to explore the effect of polymorphisms of these genes on the risk of lung cancer.
METHODS: Six single nucleotide polymorphisms (SNPs) were genotyped using a MassARRAY platform in a case-control cohort including 550 patients with lung cancer and 550 healthy controls.
RESULTS: The rs4845626-T and rs4329505-C alleles were associated with a decreased risk of lung cancer (p < 0.001), while the rs745986-G and rs2245121-A alleles were correlated with an increased risk of lung cancer (p < 0.01). The rs4845626-GT/GG and rs4329505-TC genotypes were protective against lung cancer (p < 0.001). However, the rs745986-AG and rs2245121-AG/AA genotypes were associated with an increased risk of lung cancer (p < 0.01). Stratification analysis showed that the rs4845626 and rs4329505 polymorphisms of IL6R were associated with a reduced risk of lung cancer in both smokers and nonsmokers (p < 0.05). However, rs892690, rs745986 and rs2115819 of ALOX5 were associated with an increased risk of disease in nonsmokers, while rs2245121 of SFTPD was correlated with a higher risk of disease in smokers (p < 0.05).
CONCLUSION: Our results provide candidate SNPs for early screening for lung cancer and new clues for further study of the pathogenesis of the disease.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Arachidonate 5-lipoxygenase (ALOX5); Interleukin 6 receptor (IL6R); Lung cancer; Polymorphisms; Surfactant protein D (SFTPD)

Mesh:

Substances:

Year:  2020        PMID: 31918059     DOI: 10.1016/j.intimp.2019.106155

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  6 in total

1.  Low expression of IL6R predicts poor prognosis for lung adenocarcinoma.

Authors:  Gaofeng Sun; Tianyi Wang; Muqi Shi; Hao Zhou; Jinjie Wang; Zhanghao Huang; Haijian Zhang; Jiahai Shi
Journal:  Ann Transl Med       Date:  2021-07

2.  CYP4B1 is a prognostic biomarker and potential therapeutic target in lung adenocarcinoma.

Authors:  Xiaoling Liu; Yichen Jia; Changyuan Shi; Dechen Kong; Yuanming Wu; Tiantian Zhang; Anjie Wei; Dan Wang
Journal:  PLoS One       Date:  2021-02-16       Impact factor: 3.240

3.  Pan-Cancer Analysis Reveals the Multidimensional Expression and Prognostic and Immunologic Roles of VSTM2L in Cancer.

Authors:  Shuyi Zhang; Hailin Xiong; Jiahui Yang; Xia Yuan
Journal:  Front Mol Biosci       Date:  2022-01-27

4.  Screening and Validation of a Carvacrol-Targeting Viability-Regulating Protein, SLC6A3, in Liver Hepatocellular Carcinoma.

Authors:  Xieling Yin; Hongjian Chen; Shi Chen; Suqing Zhang
Journal:  Dis Markers       Date:  2022-03-30       Impact factor: 3.434

5.  A ferroptosis-related gene signature for overall survival prediction and immune infiltration in lung squamous cell carcinoma.

Authors:  Ti-Wei Miao; De-Qing Yang; Fang-Ying Chen; Qi Zhu; Xin Chen
Journal:  Biosci Rep       Date:  2022-08-31       Impact factor: 3.976

6.  Identification of molecular subtypes in lung adenocarcinoma based on DNA methylation and gene expression profiling-a bioinformatic analysis.

Authors:  Shuying Wang; Xiaoxing Liang; Ruomi Guo; Jiao Gong; Xiaolong Zhong; Yulin Liu; Deqing Wang; Yanmei Hao; Bo Hu
Journal:  Ann Transl Med       Date:  2022-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.